Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$89.00 USD
+0.22 (0.25%)
Updated Oct 25, 2024 04:00 PM ET
After-Market: $89.00 0.00 (0.00%) 7:44 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$89.00 USD
+0.22 (0.25%)
Updated Oct 25, 2024 04:00 PM ET
After-Market: $89.00 0.00 (0.00%) 7:44 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Galapagos Begins Dosing With GLPG3970 in Psoriasis Study
by Zacks Equity Research
Galapagos (GLPG) doses the first patient in an early-stage study on its Toledo compound GLPG3970 for treating psoriasis. The same is also being studied for ulcerative colitis and rheumatoid arthritis.
Regeneron Surges on Coronavirus Treatment Development Efforts
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for the novel coronavirus.
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
Regeneron's Coronavirus Antibody Cocktail Study Data Promising
by Zacks Equity Research
Regeneron (REGN) announces encouraging initial data from its seamless phase I/II/III study, evaluating antibody cocktail candidate, REGN-COV2, in non-hospitalized patients with COVID-19.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.85, moving +0.96% from the previous trading session.
Gilead & Galapagos' RA Drug Receives Approval in Europe
by Zacks Equity Research
Gilead (GILD) and partner Galapagos win approval for their rheumatoid arthritis (RA) drug in Europe.
Galapagos Gets First Commercial Drug With Jyseleca Approval
by Zacks Equity Research
Galapagos (GLPG) and Gilead announce approval of Jyseleca in Europe as a treatment for rheumatoid arthritis patients.
The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman Sachs
Gilead's Rheumatoid Arthritis Drug Gets Approval in Japan
by Zacks Equity Research
Gilead's (GILD) rheumatoid arthritis drug, Jyseleca, wins approval in Japan.
Top Stock Reports for Anheuser-Busch, Gilead & Canadian National
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Anheuser-Busch InBev (BUD), Gilead Sciences (GILD) and Canadian National Railway (CNI).
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $64.21, marking a -1.29% move from the previous day.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
by Ritujay Ghosh
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies
by Zacks Equity Research
Eli Lilly (LLY) is developing several potential neutralizing antibodies to treat COVID-19.
Rigel Announces Sponsored Mid-Stage Coronavirus Therapy Study
by Zacks Equity Research
Rigel Pharmaceuticals (RIGL) is developing its thrombocytopenia drug, Tavalisse, as a potential treatment for hospitalized COVID-19 patients.
Roche's Actemra Meets Goal in Phase III Coronavirus Study
by Zacks Equity Research
Roche's (RHHBY) phase III study, EMPACTA, evaluating Actemra in patients with COVID-19-associated pneumonia, meets primary endpoint.
Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Williams-Sonoma, Tanger Factory Outlet, Gilead Sciences, Immunomedics and Jounce Therapeutics highlighted as Zacks Bull and Bear of the Day
Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4
by Zacks Equity Research
The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.
Lilly's Coronavirus Antibody Shows Positive Effect in Phase II
by Zacks Equity Research
Lilly (LLY) is developing two coronavirus neutralizing antibody candidates as potential treatment for hospitalized COVID-19 patients. Treatment with one antibody candidate reduces hospitalization rate.
Gilead's Oncology Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
Gilead's (GILD) magrolimab obtains Breakthrough Therapy designation in the United States for the treatment of newly-diagnosed myelodysplastic syndrome (MDS).
M&A ETFs Sizzling on Recent Deal Activities
by Sweta Killa
After tumbling to the lowest level in more than a decade in the second quarter, global M&A activity gathered steam in September following the flurry of latest deal activities.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $66.20, moving -0.21% from the previous trading session.